Cathepsin B as a Prognostic Marker for Inflammatory Breast Cancer
Author Information
Author(s): Nouh Mohamed A, Mohamed Mona M, El-Shinawi Mohamed, Shaalan Mohamed A, Cavallo-Medved Dora, Khaled Hussein M, Sloane Bonnie F
Primary Institution: National Cancer Institute, Cairo University
Hypothesis
Is cathepsin B a potential prognostic marker for inflammatory breast cancer?
Conclusion
Cathepsin B may serve as a potential prognostic marker for lymph node metastasis in inflammatory breast cancer.
Supporting Evidence
- CTSB and cav-1 were overexpressed in IBC compared to non-IBC tissues.
- There was a significant positive correlation between CTSB expression and the number of positive metastatic lymph nodes in IBC.
- IBC patients were significantly younger at diagnosis compared to non-IBC patients.
Takeaway
This study found that a protein called cathepsin B is more active in a dangerous type of breast cancer, which might help doctors predict how likely it is to spread.
Methodology
The study involved 23 inflammatory breast cancer patients and 27 non-inflammatory breast cancer patients, analyzing tissue samples for cathepsin B and caveolin-1 expression using immunohistochemistry and immunoblotting.
Potential Biases
Potential biases may arise from the selection of patients and the retrospective nature of the study.
Limitations
The study was limited to a small sample size and specific patient demographics.
Participant Demographics
IBC patients aged 29-60 years (mean age 40.9), non-IBC patients aged 33-67 years (median age 49.9).
Statistical Information
P-Value
0.0478
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website